About
Karen Uhlmann is a Berlin-based biotech executive and co-founder of OMEICOS Therapeutics, where she serves as Vice President Operations & IP. Public company materials describe her as having more than 20 years of experience in IP asset management, commercialization, fundraising, and company building. She appears in the broader biotech ecosystem through public commentary on Berlin life sciences and advisory-committee service, but there is no reliable evidence that she operates an investment fund or deploys personal capital as an investor.
Areas of interest
biotechcardiovascular therapeuticsinflammatory diseaseophthalmologyintellectual propertycommercializationstartup operationsfundraising